Jan 18, 2017

Even short-term monopoly pricing greatly benefits drug companies

Flickr Creative Commons

If policymakers offer a short-term extension of monopoly pricing for old drugs to treat rare diseases, drug companies could reap a lot of profits quickly at the expense of the public, according to a new study by Harvard physicians in the journal Health Affairs.

What they found: Researchers looked at 13 drugs, like AbbVie's blockbuster Humira, that later gained supplemental approval as "orphan drugs" for people with rare diseases. They modeled what the financial returns would look like with a six-month extension of monopoly pricing in proposed federal legislation. The median net returns would have surpassed $82 million.

The money quote: "The incentives offered under the [legislation] would serve as windfalls to manufacturers that would have sought approval of their drugs for relevant rare disease populations even without those incentives." Instead, researchers said policymakers should consider just covering the cost of clinical trials or offering tax credits in the place of the full-blown market exclusivity extension.

Perfect timing: The study coincides with a major Kaiser Health News investigation that found drug companies routinely repurpose blockbuster drugs as orphan medicines to milk more sales and profits from new market exclusivity.

Go deeper

Serological coronavirus testing could be key to economic reopening

Illustration: Sarah Grillo/Axios

America's economy won't reopen anytime soon, despite frantic CEO whispers, but a glimmer of hope may be emerging in the form of serological testing.

Why it matters: Serologic tests aren't to determine whether or not you're infected with coronavirus. They are to determine if you have potential immunity that could allow you to safely return to work.

Government tech struggles to dole out coronavirus stimulus cash

Illustration: Eniola Odetunde/Axios

Tech challenges are hampering federal and state government efforts to get funds from the $2 trillion coronavirus relief law into the hands of newly unemployed workers and struggling small businesses who need it.

Why it matters: Many businesses and individuals need the money now for essentials, including meeting payroll and paying rent.

U.S. coronavirus updates: Death toll passes 9,600

Data: The Center for Systems Science and Engineering at Johns Hopkins; Map: Andrew Witherspoon/Axios

Recorded deaths from the novel coronavirus surpassed 9,600 in the U.S. on Monday, per Johns Hopkins data. More than 1,000 people in the U.S. have died of coronavirus-related conditions each day since April 1.

Why it matters: U.S. Surgeon General Jerome Adams said on Sunday the coming week will be "the hardest and saddest week of most Americans' lives" — calling it our "our Pearl Harbor, our 9/11 moment."

Go deeperArrowUpdated 2 hours ago - Health